Submission of Investor Complaints for the quarter and year ended 31st March, 2026
Awaiting price reaction for this filing.
MPS Pharmaa Limited has submitted a routine regulatory filing to BSE under SEBI LODR Regulation 13(3), disclosing the status of investor complaints for Q4 FY2026 (January to March 2026). The statement shows NIL (zero) investor complaints across all categories - pending at the beginning of the quarter, received during the quarter, disposed of, and remaining unresolved at the end of the quarter. The company also confirmed its name change from Advik Laboratories Limited to MPS Pharmaa Limited. This is a standard compliance filing required quarterly by listed companies.
Zero investor complaints indicates smooth shareholder relations and no major grievances from investors during the quarter. This is a neutral-to-positive signal for shareholders as it suggests no significant operational or investor-related issues were raised.